Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055120 · ClinicalTrials.gov registry record · Phase 4
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
A Phase 4 study of HIV Infections and AIDS-Related Opportunistic Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 4
- Development phase
- 283
- Enrollment target
- 20
- Study locations
NCT00055120 is a Phase 4 study of HIV Infections and AIDS-Related Opportunistic Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 283 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00055120, a Phase 4 study of HIV Infections and AIDS-Related Opportunistic Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 283 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs who deferred beginning anti-HIV drugs until after recovering from the OI.
Conditions Studied
Interventions
- DRUG Stavudine
- DRUG Emtricitabine/tenofovir disoproxil fumarate
- DRUG Lopinavir/ritonavir
Study Locations (20)
California
- University of California, Davis Medical Center - Sacramento
- University of California, San Diego Antiviral Rese - San Diego
- San Francisco General Hospital - San Francisco
- San Mateo County AIDS Program - Stanford
- Santa Clara Valley Medical Center - Stanford
- Stanford Univ - Stanford
- Willow Clinic - Stanford
- Harbor General/UCLA - Torrance
Indiana
- Methodist Hospital of Indiana - Indianapolis
- Indiana University Hosp - Indianapolis
- Wishard Hospital - Indianapolis
Illinois
- Northwestern University - Chicago
- Cook County Hospital Core Center - Chicago
Maryland
- University of Maryland, Institute of Human Virology - Baltimore
- Johns Hopkins University - Baltimore
Massachusetts
- Harvard (Massachusetts General Hospital) - Boston
- Beth Israel Deaconess - West Campus - Boston
Colorado
- University of Colorado Health Sciences Center, Denver - Denver
Florida
- Univ of Miami - Miami
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2003-03 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055120
The ClinicalTrials.gov registry entry for NCT00055120 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (36% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Stavudine is the first listed.
NCT00055120 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Indiana, Illinois.
Frequently Asked Questions
What is clinical trial NCT00055120 about?
NCT00055120 is a clinical study titled "When to Start Anti-HIV Drugs in Patients With Opportunistic Infections". The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs w...
What is the current status of trial NCT00055120?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 283 participants. The study started on 2003-03. Estimated completion is 2007-08.
What conditions does trial NCT00055120 study?
This clinical trial studies the following conditions: HIV Infections, AIDS-Related Opportunistic Infections.
What interventions are being tested in trial NCT00055120?
The interventions under investigation include: Stavudine (DRUG), Emtricitabine/tenofovir disoproxil fumarate (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00055120?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055120 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.